First survival advantage for first line CDK 4/6 inhibitor in HR+, HER2- advanced breast cancer

The first report of a significant and clinically meaningful overall survival benefit for postmenopausal women with HR-positive, HER2 negative advanced breast cancer has been achieved by adding a CDK 4/6 inhibitor to first-line hormonal treatment, according to findings presented at ESMO 2021. The addition of ribociclib plus the aromatase inhibitor letrozole prolonged survival by one ...

Already a member?

Login to keep reading.

© 2022 the limbic